A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetic Characteristics of TQC2938 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

The study is a Phase II, multicenter, double-blind, randomized, parallel, placebo-controlled clinical trial designed to evaluate the efficacy, safety, tolerability, and pharmacokinetic characteristics of TQC2938 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). It is anticipated that 256 subjects will be enrolled.

Start Date01 Apr 2025

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NCT06449859

/ Active, not recruitingPhase 1

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Profile of TQC2938 Injection in Healthy Adult Subjects After Single and Multiple Administration

The study is designed in two phases: single-dose administration and multiple-dose administration. A randomized, double-blind, placebo-controlled trial design was used to evaluate the safety, tolerability, pharmacokinetic characteristics and immunogenicity of TQC2938 injection in healthy adults.

Start Date13 Jun 2023

Sponsor / Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

CTR20230916

/ RecruitingPhase 1

评价TQC2938注射液在健康成人受试者中单次和多次给药的安全性、耐受性、药代动力学特征的Ⅰ期临床试验。

[Translation] A Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of TQC2938 injection in healthy adult subjects.

主要目的:评价TQC2938注射液在健康受试者中单/多次给药的安全性和耐受性；次要目的:评价TQC2938注射液在健康受试者中单/多次给药的药代动力学特征和免疫原性。

[Translation]

Primary objective: To evaluate the safety and tolerability of single/multiple administrations of TQC2938 injection in healthy subjects; Secondary objective: To evaluate the pharmacokinetic characteristics and immunogenicity of single/multiple administrations of TQC2938 injection in healthy subjects.

Start Date07 Jun 2023

Sponsor / Collaborator

Nanjing Shunxin Pharmaceutical Co., Ltd.

100 Clinical Results associated with TQC2938

100 Translational Medicine associated with TQC2938

100 Patents (Medical) associated with TQC2938

100 Deals associated with TQC2938

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	Phase 2	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	01 Apr 2025
Asthma	Phase 1	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	13 Jun 2023
Rhinitis, Allergic, Seasonal	IND Approval	China	Nanjing Shunxin Pharmaceutical Co., Ltd.	31 Mar 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis